Meisner Derek M 4

What Happened

• Derek M. Meisner, Chief Legal Officer & Corporate Secretary of Acumen Pharmaceuticals (ticker: ABOS), exercised employee stock options and then sold the resulting shares. On Jan 26, 2026 he exercised 15,085 options at $1.85 ($27,907) and sold those 15,085 shares in the open market for a weighted average price of $3.00 (proceeds ~$45,263). On Jan 28, 2026 he exercised another 2,671 options at $1.85 ($4,941) and sold those 2,671 shares at a weighted average $3.00 (proceeds ~$8,017). Total exercised shares = 17,756 (exercise cost $32,848); total sale proceeds ≈ $53,280 (gross difference ≈ $20,432).

Key Details

• Transaction dates and prices:
  • 2026-01-26: Exercised 15,085 options at $1.85; sold 15,085 shares at weighted avg $3.00 (sales ranged $3.0000–$3.0100).
  • 2026-01-28: Exercised 2,671 options at $1.85; sold 2,671 shares at weighted avg $3.00.
• Transaction codes: M = option exercise/acquisition of shares; S = open-market sale.
• Sales were automatic under a pre-established Rule 10b5-1 trading plan adopted March 29, 2025 (footnote F1).
• Weighted-average sale price reported; the filer noted sales occurred in multiple trades between $3.0000–$3.0100 (footnote F2).
• Vesting note for the options: they vest in 48 equal monthly installments over four years from grant, subject to continued service (footnote F3).
• Shares owned after transaction: not specified in this Form 4.
• Filing: Reported on Jan 28, 2026 for transactions on Jan 26 and Jan 28 — appears to be timely (no late filing noted).

Context

• These filings show an option exercise immediately followed by open-market sales (common practice to cover exercise cost or diversify). The sales were conducted under a 10b5-1 plan, which typically means the trades were pre-scheduled and not spontaneous decisions. This is routine insider activity; it is factual reporting and not a statement of the insider’s views on the company’s prospects.